Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

5AEP

Novel pyrrole carboxamide inhibitors of JAK2 as potential treatment of myeloproliferative disorders

Summary for 5AEP
Entry DOI10.2210/pdb5aep/pdb
DescriptorTYROSINE-PROTEIN KINASE JAK2, 1-(5-chloro-2-methylphenyl)-4-(pyrrolo[2,1-f][1,2,4]triazin-4-yl)-1H-pyrrole-2-carboxamide (3 entities in total)
Functional Keywordstransferase, protein kinase, jak2, myeloproliferative disorders, tumour cell proliferation inhibition, anti-cancer agents
Biological sourceHOMO SAPIENS (HUMAN)
Total number of polymer chains1
Total formula weight35549.78
Authors
Primary citationBrasca, M.G.,Gnocchi, P.,Nesi, M.,Amboldi, N.,Avanzi, N.,Bertrand, J.,Bindi, S.,Canevari, G.,Casero, D.,Ciomei, M.,Colombo, N.,Cribioli, S.,Fachin, G.,Felder, E.R.,Galvani, A.,Isacchi, A.,Motto, I.,Panzeri, A.,Donati, D.
Novel Pyrrole Carboxamide Inhibitors of Jak2 as Potential Treatment of Myeloproliferative Disorders.
Bioorg.Med.Chem., 23:2387-, 2015
Cited by
PubMed Abstract: Compound 1, a hit from the screening of our chemical collection displaying activity against JAK2, was deconstructed for SAR analysis into three regions, which were explored. A series of compounds was synthesized leading to the identification of the potent and orally bioavailable JAK2 inhibitor 16 (NMS-P830), which showed an encouraging tumour growth inhibition in SET-2 xenograft tumour model, with evidence for JAK2 pathway suppression demonstrated by in vivo pharmacodynamic effects.
PubMed: 25882525
DOI: 10.1016/J.BMC.2015.03.059
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (1.95 Å)
Structure validation

229183

PDB entries from 2024-12-18

PDB statisticsPDBj update infoContact PDBjnumon